To include your compound in the COVID-19 Resource Center, submit it here.

Boehringer, MiNA strike NASH development deal

Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered with MiNA Therapeutics Ltd. (London, U.K.) to develop fibrotic liver disease therapeutics based on MiNA’s small activating RNA (saRNA) technology

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE